Loading patent…
AssigneesSanofi-Aventis Deutschland GmbH, Aventis Pharma S.A.
InventorsHeinz-Werner Kleemann, Armin Hofmeister, Jean-Christophe Carry, Baptiste Ronan, Serge Mignani, Antony Bigot
Estimating the term…
The present invention relates to the novel isoindolone derivatives of the formula I in which R1 to R6 have the meanings stated in the claims. The inventive compounds are suitable as antiarrhythmic medicaments with a cardioprotective component for infarction prophylaxis and infarction treatment and for the treatment of angina pectoris. They also inhibit in a preventive manner the pathophysiological processes associated with the development of ischemia-induced damage, in particular in the triggering of ischemia-induced cardiac arrhythmias and of heart failure.
1-21. (canceled)
A method for the treatment or prophylaxis of acute or chronic damage, disorders or indirect sequelae of organs and tissues caused by ischemic or reperfusion events, for the treatment or prophylaxis of arrhythmias, of life-threatening cardiac ventricular fibrillation, of myocardial infarction, of angina pectoris, for the treatment or prophylaxis of ischemic states of the heart, of ischemic states of the peripheral and central nervous system or of stroke or of ischemic states of peripheral organs and tissues, for the treatment or prophylaxis of states of shock, of diseases in which cellular proliferation represents a primary or secondary cause, of cancer, of metastasis, of prostate hypertrophy and of prostate hyperplasia, of atherosclerosis or of disturbances of lipid metabolism, of high blood pressure, of disorders of the central nervous system, for the treatment or prophylaxis of non-insulin-dependent diabetes mellitus (NIDDM) or late damage from diabetes, of thromboses, of disorders resulting from endothelial dysfunction, of intermittent claudication, for the treatment or prophylaxis of fibrotic disorders of internal organs, fibrotic disorders of blood vessels, for the treatment or prophylaxis of heart failure or of congestive heart failure, of acute or chronic inflammatory disorders, of disorders caused by protozoa, of malaria and of coccidiosis in poultry, for preserving and storing transplants for surgical procedures, for preventing age-related tissue change, for inhibiting aging, for prolonging life, for the treatment and reduction of the cardiotoxic effects in thyrotoxicosis, or for producing a diagnostic aid, said method comprising the use or administration of an effective amount of a compound of formula I:
A method for the treatment or prophylaxis of acute or chronic damage, disorders or indirect sequelae of organs and tissues caused by ischemic or reperfusion events, for the treatment or prophylaxis of arrhythmias, of life-threatening cardiac ventricular fibrillation, of myocardial infarction, of angina pectoris, for the treatment or prophylaxis of ischemic states of the heart, of ischemic states of the peripheral and central nervous system or of stroke or of ischemic states of peripheral organs and tissues, for the treatment or prophylaxis of states of shock, of diseases in which cellular proliferation represents a primary or secondary cause, of cancer, of metastasis, of prostate hypertrophy and of prostate hyperplasia, of atherosclerosis or of disturbances of lipid metabolism, of high blood pressure, of disorders of the central nervous system, for the treatment or prophylaxis of non-insulin-dependent diabetes mellitus (NIDDM) or late damage from diabetes, of thromboses, of disorders resulting from endothelial dysfunction, of intermittent claudication, for the treatment or prophylaxis of fibrotic disorders of internal organs, fibrotic disorders of blood vessels, for the treatment or prophylaxis of heart failure or of congestive heart failure, of acute or chronic inflammatory disorders, of disorders caused by protozoa, of malaria and of coccidiosis in poultry, for preserving and storing transplants for surgical procedures, for preventing age-related tissue change, for inhibiting aging, for prolonging life, for the treatment and reduction of the cardiotoxic effects in thyrotoxicosis, or for producing a diagnostic aid, said method comprising the use or administration of an effective amount of a compound of formula I:
A method for reducing the cardiotoxic and cytotoxic properties of a medicament or active ingredient having cardiotoxic and cytotoxic properties comprising combining an effective amount of a compound of Formula I with such medicament or active ingredient, wherein the compound of Formula I is:
A method for the treatment of or prophylaxis of acute or chronic damage, disorders or indirect sequelae of organs and tissues caused by ischemic or reperfusion events comprising the administration of an effective amount of a compound of Formula I alone or in combination with other medicaments or active ingredients, wherein the compound of Formula I is:
A method for the treatment of life-threatening cardiac ventricular fibrillation comprising the administration of an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, alone or in combination with other medicaments or active ingredients, wherein the compound of Formula I is:
A method for the treatment or prophylaxis of metastasis comprising the administration of a compound of Formula I or a pharmaceutically acceptable salt thereof, alone or in combination with other medicaments or active ingredients, wherein the compound of Formula I is:
A method for the treatment or prophylaxis of fibrotic disorders of the heart, of heart failure or of congestive heart failure comprising the administration of an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, alone or in combination with other medicaments or active ingredients, wherein the compound of Formula I is:
A method for the treatment or prophylaxis of diseases which are related to NHE comprising the administration of an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, alone or in combination with other medicaments or active ingredients, wherein the compound of Formula I is:
A method for the treatment or prophylaxis of diseases which are related to NHE1 comprising the administration of an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, alone or in combination with other medicaments or active ingredients, wherein the compound of Formula I is:
Dependencies are inferred from the claim text.